According to the allegations, Insys used a combination of tactics to increase prescriptions for the Subsys, including falsifying medical records, misleading insurance companies and providing kickbacks to doctors who were cooperating with the company in promoting the use of the drug.
The allegations state that due to the high cost associated with Subsys, most insurers wouldn't pay for it unless it was approved in advance, a process called "prior-authorization." However, Insys realized shortly after the opioid pain medication was approved, that there weren’t enough cancer patients to make the drug commercially viable.
The Senate report documents an elaborate plan to fool insurers into paying for Subsys prescriptions. Specifically, the report shows that beginning in 2014, Insys employees would set themselves up so that it appeared as if they were working for doctors, thereby being in a position to request the prescription. When someone needed to obtain prior approval for a Subsys prescription, it was actually an Insys employee who called the insurer and its affiliates to persuade them to approve the prescription. Believing they were speaking with people who worked for the doctors requesting the prescription, the insurers would issue an approval.
READ MORE Opioid Addiction Legal Help LEGAL NEWS
In December 2016, six former Insys executives, including its former CEO, were criminally charged with fraud and racketeering related to Subsys. Federal prosecutors described a "nationwide conspiracy to bribe medical practitioners to unnecessarily prescribe a fentanyl-based pain medication and defraud health care insurers." CNN.com
According to McCaskill’s report, provisional statistics from the Centers for Disease Control on the opioid epidemic show “drug deaths from fentanyl more than doubled from 2015 to 2016 and deaths involving synthetic opioids, mostly fentanyls, has risen to more than 20,000 from 3,000 in just three years.”